Viracta Therapeutics

+$0.04 (+1.93%) Today
$0.00 (0.00%) As of 12:00 AM UTC after-hours

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell VIRX and other ETFs, options, and stocks.

About VIRX

Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas.

CEO
Ivor Royston
Employees
24
Headquarters
Cardiff, California
Founded
1998

VIRX Key Statistics

Market cap
79.10M
Price-Earnings ratio
—
Dividend yield
—
Average volume
212.34K
High today
$2.13
Low today
$1.98
Open price
$2.13
Volume
170.71K
52 Week high
$13.08
52 Week low
$1.82

VIRX Earnings

-$5.22
-$3.48
-$1.74
$0.00
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Q3 FY21
Q4 FY21
Q1 FY22
Estimated
-$0.31 per share
Actual
-$0.28 per share
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure